What Bausch + Lomb (BLCO) Said on Its Q3 Earnings Call

Bausch + Lomb NYSE: BLCO reported third-quarter revenue growth across all three business segments, raised its full-year outlook for the third time in 2026 and highlighted continued margin expansion and cash generation as interim Chief Executive Officer Tom Appio outlined priorities following the company's leadership transition.

MarketBeat • 18 hours ago

Bausch + Lomb Announces Publication of Multinational Survey Results Highlighting the Burden of Dry Eye Symptoms and Opportunities for Improved Awareness and Patient Education

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the publication of results from a multinational survey examining symptoms, interactions with health care professionals (HCPs) and treatment experiences to better understand consumer perspectives on dry eye. The findings showed that self-reported dry eye symptoms were more common than reported HCP diagnosis and h.

Business Wire • 13 hours ago

Bausch + Lomb Swings to Profit and Lifts Outlook for Year

Bausch + Lomb increased its full-year outlook after logging a third-quarter profit, benefiting from rising revenue across its three segments.

WSJ • Oct 28, 2026

Bausch + Lomb Corporation (BLCO) Q3 2026 Earnings Call Transcript

Bausch + Lomb Corporation (BLCO) Q3 2026 Earnings Call Transcript

Seeking Alpha • Oct 28, 2026

Bausch + Lomb Posts Strong Third-Quarter Performance, Raises Full-Year 2026 Guidance

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2026 financial results. “Our third-quarter performance reflects the strength and breadth of the business, with growth across all three segments and continued expansion in profitability,” said Thomas J. Appio, chairman and interim CEO, Bausch + Lomb. “We have delivered against the commitments ou.

Business Wire • Oct 28, 2026

Bausch + Lomb (BLCO) Surpasses Q3 Earnings and Revenue Estimates

Bausch + Lomb (BLCO) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.18 per share a year ago.

Zacks Investment Research • Oct 28, 2026

Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that Bausch + Lomb Board of Directors Chairman Thomas J. Appio has been appointed interim chief executive officer, effective immediately. Appio will continue to serve as CEO of Bausch Health while assuming leadership of Bausch + Lomb. Appio was appointed chairman of the Bausch + Lomb Board of Dir.

Business Wire • Oct 12, 2026

Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced progress in the development of BL1243 (tonabersat), an investigational oral treatment for dry age-related macular degeneration (AMD), following a constructive meeting with the U.S. Food and Drug Administration (FDA). The discussion provided greater clarity on the clinical development path for BL1243. If successf.

Business Wire • Oct 6, 2026

Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter financial results on Wednesday, Oct. 28, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the c.

Business Wire • Oct 5, 2026

BLCO Gains European CE Mark for Next-Gen SeeLyra Femtosecond Laser

Bausch + Lomb gains European CE Mark approval for SeeLyra, expanding its surgical portfolio with a compact laser platform for cataract and corneal procedures.

Zacks Investment Research • Sep 14, 2026